Amgen

Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings
Fierce Biotech
Tue, 10/31/23 - 10:19 am
Amgen
earnings
Teneobio
bispecifics
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Fierce Pharma
Tue, 10/24/23 - 07:54 pm
Amgen
Horizon Therapeutics
layoffs
M&A
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Mon, 10/23/23 - 10:30 am
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Fri, 10/20/23 - 11:34 am
Amgen
bispecific antibodies
T-cell engager
tarlatamab
clinical trials
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
BioSpace
Fri, 10/6/23 - 11:37 am
Amgen
Horizon Therapeutics
FTC
M&A
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Amgen
Lumakras
FDA
KRAS inhibitors
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Wed, 10/4/23 - 11:08 am
Amgen
Lumakras
non-small cell lung cancer
FDA
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
Reuters
Tue, 10/3/23 - 10:23 am
Amgen
FDA
Lumakras
lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Thu, 09/28/23 - 10:42 am
Amgen
Neumora
IPOs
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Thu, 09/21/23 - 06:35 pm
Amgen
expert panels
oncology
cancer
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Wed, 09/20/23 - 08:59 am
Amgen
Horizon Therapeutics
FTC
antitrust
M&A
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
Medical Marketing and Media
Fri, 09/1/23 - 12:40 pm
FTC
Amgen
Horizon Therapeutics
M&A
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
BioSpace
Mon, 08/28/23 - 12:06 pm
FTC
Amgen
Horizon Therapeutics
M&A
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Mon, 08/28/23 - 12:02 pm
Amgen
cardiovascular disease
olpasiran
clinical trials
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
Fierce Pharma
Thu, 08/24/23 - 11:38 am
Amgen
Horizon Therapeutics
M&A
FTC
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Mon, 08/21/23 - 06:56 pm
Amgen
Lumakras
KRAS inhibitors
FDA
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
Wed, 08/16/23 - 10:16 am
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Wed, 08/9/23 - 11:55 am
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors

Pages